DrugPatentWatch Database Preview

Pfizer Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?

PFIZER has one hundred and eighty-nine approved drugs.

There are twenty-nine US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are six hundred and seventy patent family members on PFIZER drugs in sixty-six countries and one hundred and ninety-eight supplementary protection certificates in nineteen countries.

Summary for Pfizer

International Patents:	670
US Patents:	29
Tradenames:	154
Ingredients:	125
NDAs:	189
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Drugs and US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992		DISCN	No	No
Pfizer	SINEQUAN	doxepin hydrochloride	CAPSULE;ORAL	016798-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-001	Nov 21, 2018		RX	Yes	No
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-001	Nov 21, 2018		RX	Yes	No	10,414,748		Y	Y
Pfizer	PFIZERPEN G	penicillin g potassium	TABLET;ORAL	060075-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	PFIZERPEN G	penicillin g potassium	TABLET;ORAL	060075-004	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MICRONASE	glyburide	TABLET;ORAL	017498-003	May 1, 1984	3,507,954
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994	5,082,668
Pfizer	MINIZIDE	polythiazide; prazosin hydrochloride	CAPSULE;ORAL	017986-001	Approved Prior to Jan 1, 1982	3,511,836
Pfizer	CORVERT	ibutilide fumarate	INJECTABLE;INJECTION	020491-001	Dec 28, 1995	5,155,268
Pfizer	GLYNASE	glyburide	TABLET;ORAL	020051-002	Mar 4, 1992	3,507,961
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-001	Oct 1, 1999	4,959,366

Paragraph IV (Patent) Challenges for PFIZER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	2 mg/mL, 100 mL bag		2009-12-29
	Tablets	5 mg		2016-11-07
	Delayed-release Tablets	50 mg/0.2 mg		2009-06-29
	Extended-release Tablets	11 mg		2016-11-07
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Capsules	75 mg, 100 mg and 125 mg		2019-02-04
	Capsules	0.125 mg, 0.25 mg, and 0.5 mg		2014-05-01
	Tablets	600 mg		2005-12-21
	Injection	2 mg/mL, 300 mL bag		2009-09-01
	Tablets	1 g		2005-08-23
	Delayed-release Tablets	75 mg/0.2 mg		2008-11-28
	Extended-release Tablets	4 mg and 8 mg		2012-10-31
	Injection	20 mg/mL, 2 mL and 5 mL vials		2004-07-26
	Capsules	5 mg and 10 mg		2005-06-21
	For Injection	500 mg/vial		2011-06-17
	Oral Suspension	100 mg/5 mL		2009-08-03

International Patents for Pfizer Drugs

Country	Patent Number	Estimated Expiration
Japan	6345728
African Regional IP Organization (ARIPO)	2377
Iceland	8382
Iceland	2124
Slovenia	1235830
Tunisia	SN00239

Supplementary Protection Certificates for Pfizer Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
1746976	2017C/027	Belgium		PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1470124	2017/009	Ireland		PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESTER, AMIDE OR PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/16/1147/001 EU/1/16/1147/006 20161109
1666481	1790038-2	Sweden		PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REG. NO/DATE: EU/1/17/1178 20170324
0770388	PA2009004,C0770388	Lithuania		PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
1077912	07C0050	France		PRODUCT NAME: FESOTERODINE ET SES SELS AVEC DES ACIDES PHYSIOLOGIQUEMENT ACCEPTABLES NOTAMMENT L ACIDE FUMARIQUE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/386/001 DU 20070420; REGISTRATION NO/DATE AT EEC: EU/1/07/386/001 DU 20070420

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pfizer
• Pfizer Global
• Pfizer Inc
• Pfizer Labs
• Pfizer Pharms